**John B. Liao, MD, PhD**

**Undergraduate**

Yale University BA May 1994

New Haven, CT

**Graduate**

The George Washington University MD May 1998

School of Medicine, Washington, DC

**Graduate**

Yale University PhD May 2007

New Haven, CT

Thesis: *Studies of therapeutic vaccination and immune*

*evasion by human papillomavirus oncoproteins*

Thesis Advisor: Daniel DiMaio

**POSTGRADUATE TRAINING**

July 1998- June 2002 Internship and Residency in Obstetrics and Gynecology

The George Washington University Medical Center, Washington, DC

July 2001-June 2002 Administrative Chief Resident

Department of Obstetrics and Gynecology

The George Washington University Medical Center, Washington, DC

Aug 2002- June 2004 Postdoctoral Fellow

Molecular Oncology and Virology Program, Department of Genetics

Yale University School of Medicine, New Haven, CT

June 2007- June 2010 Fellow

Division of Gynecologic Oncology

Department of Obstetrics and Gynecology

University of Pennsylvania School of Medicine, Philadelphia, PA

**FACULTY POSITIONS**

July 2004-June 2007 Associate Research Scientist

Department of Obstetrics, Gynecology, and Reproductive Sciences

Yale University School of Medicine, New Haven, CT

Sept 2010-June 2011 Acting Instructor

Division of Gynecologic Oncology

Department of Obstetrics and Gynecology

University of Washington School of Medicine, Seattle, WA

July 2011-June 2018 Assistant Professor

Division of Gynecologic Oncology

Department of Obstetrics and Gynecology

University of Washington School of Medicine, Seattle, WA

July 2018-present Associate Professor

Division of Gynecologic Oncology

Department of Obstetrics and Gynecology

University of Washington School of Medicine, Seattle, WA

**BIBLIOGRAPHY**

**Peer Reviewed Journals**

1. **Liao JB**, Lin JY. Estrogen receptor expression in an endometrial stromal sarcoma

after tamoxifen therapy. Eur J Gynaec Oncol 2001;22:417-9. PMID: 11874071

2. Chi DS, **Liao JB**, Leon LF, Venkatraman ES, Hensley ML, Bhaskaran D, Hoskins

WJ: Identification of prognostic factors in advanced epithelial ovarian carcinoma.

Gynecol Oncol 2001;82:532-7. PMID: 11520191

3. **Liao JB,** Buhimschi CS, Norwitz ER. Normal labor: mechanism and duration.

Obstet Gynecol Clin N Am 2005 Jun;32(2):145-64. PMID: 15899352

4. DiMaio D, **Liao JB**. Human papilloma viruses and cervical cancer. Adv Virus Res

2006;66:125-59. PMID: 16877060

5. **Liao JB**. Viruses and human cancer. Yale J Biol Med. 2006;79(3-4):115-22. PMID: 17940621

6. **Liao JB**, Publicover J, Rose JK, DiMaio D. Single-dose therapeutic vaccination of

mice with vesicular stomatitis virus expressing human papillomavirus type 16 E7

proteins. Clin Vaccine Immunol 2008 May; 15(5):817-24. PMID: 18337377

March 2, 2019

7. Robinson BL, **Liao JB**, Adams SF, Randall TC. Vaginal cuff dehiscence after

robotic total laparoscopic hysterectomy. Obstet Gynecol. 2009 Aug;114(2, Part

1):369-71. PMID: 19622999

8. Kandalaft LE, Singh N, **Liao JB**, Facciabene A, Berek J, Powell DJ, Coukos G. The emergence of immunomodulation: combinatorial immuno-chemotherapy

opportunities for the next decade. Gynecol Oncol 2010 Feb;116(2):222-33. PMID:

19959212

9. **Liao JB**, Jean S, Wilkinson-Ryan I, Ford AE, Tanyi JL, Hagemann AR, Lin LL,

McGrath CM, Rubin SC. Vaginal intraepithelial neoplasia (VAIN) after radiation

therapy for gynecologic malignancies: a clinically recalcitrant entity. Gynecol

Oncol. 2011 Jan;120(1):108-12. PMID: 20937524

10. Tanyi JL, McCann G, Hagemann AR, Coukos G, Rubin SC, **Liao JB**, Chu CS.

Clinical predictors of bevacizumab-induced gastrointestinal perforation. Gynecol

Oncol 2011 Mar;120(3):464-9. PMID: 21168199

11. Dao MD, Alwan LM, Gray HJ, Tamimi HK, Goff BA, **Liao JB**. Recurrence

patterns after extended treatment with bevacizumab for ovarian, fallopian tube, and

primary peritoneal cancers. Gynecol Oncol 2013 Aug;130(2):295-9. PMID:

23632207

12. **Liao JB** and Disis ML. Therapeutic vaccines for ovarian cancer. Gynecol Oncol.

2013. Sep;130(3):667-73. PMID: 23800697

13. **Liao JB**, Yip YY, Swisher EM, Agnew K, Hellstrom KE, Hellstrom I. Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms: clinical correlates.

Gynecol Oncol 2015 Apr 9. PMID: 25866324

14. **Liao JB**, Ovenell KJ, Curtis EEM, Cecil DL, Koehnlein MR, Rastetter LR, Gad EA, Disis ML. Preservation of tumor-host immune interactions with luciferase-tagged

imaging in a murine model of ovarian cancer. J Immunother Cancer 2015 May

19;3:16. PMID: 25992288

15. Beck TL, Morse CB, Gray HJ, Goff BA, Urban RR, **Liao JB**. Route of

hysterectomy and surgical outcomes from a state-wide gynecologic oncology

population: is there a role for vaginal hysterectomy? Am J Obstet Gynecol

2016;214:348.e1-9*.* PMID: 26470825

16. **Liao JB.** Immunotherapy for gynecologic cancers. Gynecol Oncol. 2016

Jul;142(1):3-5. PMID: 27242186.

17. Martin JY, Urban RR, **Liao JB**, Goff BA. Bevacizumab toxicity in heavily

pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal

cancers. J Gynecol Oncol. 2016 Sep;27(5):e47. PMID: 27329195

18. **Liao JB**, Swensen, RE, Ovenell KJ, Hitchcock-Bernhardt K, Reichow JL, Apodaca MC, D’Amico L, Childs JS, Higgins DM, Buening B, Goff BA, Disis ML. Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer. Gynecol Oncol. 2017 Mar;144(3):480-485. PMID: 28089377

19. Morse CB, Elvin JA, Gay LM, **Liao JB**. Elevated tumor mutational burden and

prolonged clinical response to anti-PD-L1 antibody in platinum-resistant recurrent

ovarian cancer. Gynecol Oncol Rep. 2017 Jun 27;21:78-80. PMID: 28736741.

20. Shah CA, Beck T, **Liao JB**, Giannakopolous NV, Veljovich D, Paley P. Surgical

and oncologic outcomes after robotic radical hysterectomy as compared to open

radical hysterectomy in the treatment of early cervical cancer. J Gynecol Oncol.

2017 Jan:28;e82. PMID: 29027400.

21. Goff BA, Agnew K, Neradilek MB, Gray HJ, **Liao JB**, Urban RR. Combining a

symptom index, CA125 and HE4 (triple screen) to detect ovarian cancer in women

with a pelvic mass. Gynecol Oncol. 2017 Aug 28. PMID: 28860006

22. Johnson N and **Liao JB**. Novel therapeutics for ovarian cancer: The 11th biennial

Rivkin center ovarian cancer research symposium. Int J Gynecol Cancer. 2017

Nov;27(9S Suppl 5): S14-S19. PMID: 29040190.

23. **Liao JB**, Fisher CE, and Madeleine MM. Gynecologic cancers and solid organ

transplantation. Am J Trans. 2019 Feb 6. PMID: 30725527.

24. Morse CB, Toukatly M, Kilgore M, Agnew K, Bernards S, Norquist B, Pennington K, Garcia R, **Liao JB**, Swisher EM. Tumor infiltrating lymphocytes and

homologous recombination deficiency are independently associated with improved

survival in ovarian carcinoma. Gynecol Oncol. 2019 Feb 22. PMID: 30803719.

25. Wu ES, Ghezelayagh T, Barber EL, Dao MD, Zsiros E, Urban RR, Gray HJ, Goff

BA, Shah CA, Neubauer NL, Dai JY, Tanyi JL, **Liao JB**. Factors influencing

duration of bevacizumab treatment and survival in patients with recurrent ovarian,

fallopian tube, and peritoneal cancer: a multi-institution study. *Submitted to*

*Gynecologic Oncology, November 2018.*

**Books and Other Publications**

1. **Liao JB**. Sex cord-stromal and germ cell tumors of the ovary. In CS Chu and SC

Rubin (eds.), *Manual of Gynecologic Oncology*. World Scientific. 2011

2. Auci DL, Cecil DL, Herendeen D, Broussard E, **Liao JB**, Holt GE, Disis ML.

Clinical application of plasmid based cancer vaccines. In *Gene Therapy of Cancer*,

3rd edition. Elsevier, 2013

3. **Liao JB**. Management of hematologic toxicities. In *Chemotherapy of Gynecologic*

*Cancer: Society of Gynecologic Oncology Handbook*, 3rd edition. Elsevier, 2017*.*

**EDITORIAL ACTIVITY**

**Journal Peer Reviewer**

*American Journal of Obstetrics and Gynecology*

*BMC Cancer*

*Cancer Immunology and Immunotherapy*

*Cancer Immunology Research*

*Cancer Prevention Research*

*Gynecologic Oncology*

*International Journal of Cancer*

*International Journal of Gynecological Cancer*

*JAMA Oncology*

*Journal of Virology*

*Molecular Cancer*

*Oncotarget*

*Scientific Reports*

**NATIONAL COMMITTEES/ACTIVITIES**

2011 Scientific Reviewer

Ovarian Cancer Research Program

Department of Defense

Congressionally Directed Medical Research Programs

2013 Scientific Reviewer

Ovarian Cancer Research Program

Department of Defense

Congressionally Directed Medical Research Programs

2013-2014 Program Committee Member

2014 Annual Meeting on Women’s Cancer

Society of Gynecologic Oncology

2014 Scientific Reviewer

Ovarian Cancer Research Program

Department of Defense

Congressionally Directed Medical Research Programs

2015 Scientist Reviewer

Marsha Rivkin Center for Ovarian Cancer Research

2015 Scientific Reviewer

Ovarian Cancer Research Program

Department of Defense

Congressionally Directed Medical Research Programs

2016 Scientist Reviewer

Marsha Rivkin Center for Ovarian Cancer Research

2016 Scientific Reviewer

Cancer Immuno-diagnostics

Technical Emphasis Panel (TEP)

National Cancer Institute

National Institutes of Health

2016 Scientific Reviewer

Ovarian Cancer Research Program

Department of Defense

Congressionally Directed Medical Research Programs

2017 Scientific Reviewer

Ovarian Cancer Research Program

Department of Defense

Congressionally Directed Medical Research Programs

2017- LRP Ambassador

National Institutes of Health

2019 Scientific Reviewer

Clinical Oncology Study Section (CONC)

National Institutes of Health